![Figure 2. In vitro effects of alphastatin. (A) HuDMEC migration across a collagen-coated filter in response to medium alone (control) or medium containing 10 ng/mL VEGF or bFGF. (B) Tubule formation by HuDMECs on GF-reduced Matrigel in response to medium alone (control) or medium containing 10 ng/mL VEGF or bFGF, and (D) HuDMEC proliferation over a 48-hour period. (C) Tubule formation by HuDMECs exposed to either alphastatin (1000 nM) for 2 hours prior to the assay and then washed and added to the assay in the absence of alphastatin (but in the presence or absence of bFGF [10 ng/mL] or VEGF [10 ng/mL]) or HuDMECs exposed to alphastatin (1000 nM) during the assay alone (in the presence or absence of bFGF [10 ng/mL] or VEGF [10 ng/mL]). All data shown are means ± SEM. *P < .03 compared with respective “no alphastatin” groups.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/103/2/10.1182_blood-2003-07-2192/6/h80245542002.jpeg?Expires=1726834209&Signature=tF48bcfqlDNbpUusbfSEq29ec7zs2htZIFX431whZKW~0EyXhrq1Hh51x8f~Q8iHaiK2jpD47uDpAweQ4l5Ah~dh-miePs9FH5JS6JmfFmEPm0BjWqe0KAkYcmbHxK5l4ARB4dXxgwzUzNCjanHdbGdDsb70jq51exF2xlkbCzFXRT2-i1GoIab0PvR6iyNRoJJ-zLsHZaalBrmDlJvSW88hLDCaCai-XiVT88ACMmRflBZ1aYy8O-abaEgaqFgXKuo3HoWbi3IWS7nq2sSM7Xl~EW7-uoSq6Sw1hjEcrHYTiqCJiijgEYFHBZwmkd50UZ7NgP54Ks5uV3m-cxe8og__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
In vitro effects of alphastatin. (A) HuDMEC migration across a collagen-coated filter in response to medium alone (control) or medium containing 10 ng/mL VEGF or bFGF. (B) Tubule formation by HuDMECs on GF-reduced Matrigel in response to medium alone (control) or medium containing 10 ng/mL VEGF or bFGF, and (D) HuDMEC proliferation over a 48-hour period. (C) Tubule formation by HuDMECs exposed to either alphastatin (1000 nM) for 2 hours prior to the assay and then washed and added to the assay in the absence of alphastatin (but in the presence or absence of bFGF [10 ng/mL] or VEGF [10 ng/mL]) or HuDMECs exposed to alphastatin (1000 nM) during the assay alone (in the presence or absence of bFGF [10 ng/mL] or VEGF [10 ng/mL]). All data shown are means ± SEM. *P < .03 compared with respective “no alphastatin” groups.
